Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada
T T Hoang(University of British Columbia), Greg Rosenfeld(British Columbia Centre on Substance Use), Yvette Leung(University of Calgary), Jacqueline Reid(University of British Columbia), Cherry Galorport(University of British Columbia), Brian Bressler(University of British Columbia)
Cited by 5
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478